Key Takeaways:
NEW YORK — Lowey Dannenberg P.C. has launched an investigation into Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential violations of federal securities laws, the law firm announced on May 22, 2026. The inquiry follows the company's recent financial disclosures.
"Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws," the firm stated in its press release. The firm has a history of prosecuting multi-million-dollar lawsuits and has recovered billions for investors.
The investigation comes after Fulgent reported its fourth quarter and full-year 2025 financial results on February 27, 2026. The company disclosed that its full-year 2025 revenue was approximately $322.7 million, falling short of its previously updated guidance. Fulgent also reported a sequential decline in its fourth-quarter revenue.
The law firm is now calling for investors who may have suffered a loss in the company's securities to come forward. The investigation will likely focus on whether the company and its executives made misleading statements about its business and prospects, leading to investor losses. The outcome could result in a class-action lawsuit against the company.
This investigation introduces significant legal uncertainty for Fulgent Genetics, which could lead to increased stock volatility and potential financial penalties. Investors will be closely watching for any formal lawsuit filing and the company's official response to the allegations.
This article is for informational purposes only and does not constitute investment advice.
